相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy
L Norton
ONCOLOGIST (2005)
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and leukemia group B study 9763
AA Miller et al.
CLINICAL CANCER RESEARCH (2004)
Capecitabine: Fixed daily dose and continuous (noncyclic) dosing schedule
J Lokich
CANCER INVESTIGATION (2004)
Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
P Reichardt et al.
ANNALS OF ONCOLOGY (2003)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial
W Scheithauer et al.
ANNALS OF ONCOLOGY (2003)
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis
SM Blaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
SD Baker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Intermittent weekly high-dose capecitabine in combination with oxaliplatin:: a phase I/II study in first-line treatment of patients with advanced colorectal cancer
W Scheithauer et al.
ANNALS OF ONCOLOGY (2002)
Update on pharmacogenetics in cancer chemotherapy
F Innocenti et al.
EUROPEAN JOURNAL OF CANCER (2002)
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
JA O'Shaughnessy et al.
ANNALS OF ONCOLOGY (2001)
Pharmacogenetic determinants of anti-cancer drug activity and toxicity
R Danesi et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2001)
Body surface area as a determinant of pharmacokinetics and drug dosing
M Sawyer et al.
INVESTIGATIONAL NEW DRUGS (2001)
Pharmacogenomics: Unlocking the human genome for better drug therapy
HL McLeod et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)